|
|
Effect of Atorvastatin combined with Ginkgo Biloba extract on cognitive function and serum uncoupling protein 2 and brain-derived neurotrophic factor levels in patients with intracranial artery stenosis |
WANG Li |
The Second Department of Neurology, the No.2 Hospital of Baoding, Hebei Province, Baoding 071000, China |
|
|
Abstract Objective To explore the application value of Atorvastatin combined with Ginkgo Biloba extract in patients with intracranial artery stenosis. Methods A total of 112 patients with intracranial artery stenosis admitted to the Second Hospital of Baoding City from March 2019 to March 2021 were divided into the control group and the study group by random number table method, with 56 cases in each group. Patients in the control group were treated with Atorvastatin, and patients in the study group were treated with Atorvastatin and Ginkgo Biloba extract, both of which were treated continuously for three months. The cognitive function, activities of daily living, serum uncoupling protein 2(UCP2), brain-derived neurotrophic factor (BDNF), blood lipid levels and adverse reactions were compared between the two groups. Results Before treatment, there were no the statistically significant differences in scores of the mini mental state examination scale (MMSE), the activity of daily living ability scale (ADL), levels of UCP2, BDNF, total cholesterol(TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C)between the two groups (P>0.05).After treatment,MMSE,ADL scores and UCP2,BDNF,HDL-C levels of the study group were higher than those in the control group, the levels of TC, TG and LDL-C of the study group were lower than those in the control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Atorvastatin combined with Ginkgo Biloba extract can improve blood lipids, serum UCP2 and BDNF levels in patients with intracranial artery stenosis, and promote the recovery of cognitive function and activities of daily living, which is safe and reliable.
|
|
|
|
|
[1] |
王鹏宇,郑自立,冯岩,等.血管内支架成形术治疗颅内动脉狭窄[J].中国微侵袭神经外科 杂志,2019,24(3):97-100.
|
[2] |
朱清,杜雯雯,姚蓓蓓,等.银杏二萜内酯葡胺注射液治疗伴有颅内动脉狭窄的急性部分前循环脑梗死的临床疗效观察[J].北京中医药,2020,39(11):1140-1142,1146.
|
[3] |
边志杰,刘傲飞,刘云娥,等.颅内动脉重度狭窄或闭塞患者认知功能损害研究[J].中风与神经疾病杂志,2019,36(4):291-295.
|
[4] |
宋博,孙玉坤,何伟,等.阿托伐他汀联合银杏叶对脑梗死患者脑血流参数和颈动脉粥样硬化斑块的影响[J].武警医学,2018,29(5):500-503.
|
[5] |
方蒡,毛琴,李晓飞,等.银杏叶提取物联合阿托伐他汀对老年脑梗死患者疗效和血清炎症介质水平的影响[J].辽宁中医杂志,2018,45(2):319-321.
|
[6] |
周小炫,谢敏,陶静,等.简易智能精神状态检查量表的研究和应用[J].中国康复医学杂志,2016,31(6):694-696.
|
[7] |
巫嘉陵,安中平,王世民,等.脑卒中患者日常生活活动能力量表的信度与效度研究[J].中国现代神经疾病杂志,2009,9(5):464-468.
|
[8] |
刘义,杨丽华,王艳玲,等.血管内治疗与药物治疗症状性颅内动脉粥样硬化性狭窄的疗效比较研究[J].中国全科医学,2018,21(23):2867-2870.
|
[9] |
李华兴,刘爱武,丘伟贤,等.银杏二萜内酯葡胺联合奥扎格雷治疗多发颅内动脉狭窄的疗效及其对患者血管内皮功能和神经功能的影响[J].广西医学,2020,42(15):1985-1988.
|
[10] |
王辉.不同剂量阿托伐他汀对重度颅内动脉狭窄患者血脂代谢狭窄血管改善及脑血管储备的影响[J].中国药物与临床,2020,20(10):1663-1665.
|
[11] |
黄年平,向建军,黄信全,等.降脂活血片联合瑞舒伐他汀钙片治疗症状性颅内动脉粥样硬化性狭窄的疗效观察[J].中西医结合心脑血管病杂志,2020,18(6):976-979.
|
[12] |
卢波,王晓静,王沙沙.匹伐他汀钙对症状性动脉粥样硬化颅内动脉狭窄患者的影响[J].中国病案,2018,19(11):93-96.
|
[13] |
刘军贤,孙芳,杨茜,等.不同类型颅内动脉狭窄与轻度认知功能障碍相关性分析及他汀类药物干预临床研究[J].临床军医杂志,2018,46(6):700-701,704.
|
[14] |
杨毅,韩晨阳,张晓玲,等.银杏叶提取物片联合胞磷胆碱钠治疗脑白质疏松认知障碍的临床疗效及其可能机制[J].中国临床药学杂志,2018,27(2):87-90.
|
[15] |
梁盼盼,石建美.银杏叶提取物对脑动脉粥样硬化大鼠血清TG、TC 和HO-1 水平的影响[J].卒中与神经疾病,2019,26(6):668-672.
|
[16] |
陈悦悦,刘勇,李冬冬,等.常见中草药提取物及主要成分对细胞色素P450 2C9 抑制的研究进展[J].中国当代医药,2021,28(16):25-31.
|
[17] |
李进.银杏叶提取物注射液联合经颅磁刺激治疗阿尔茨海默病的临床疗效[J].中国现代医生,2021,59(12):43-46.
|
[18] |
刘进,周杰,李王文,等.不同剂量银杏叶提取物对血管性认知功能障碍大鼠认知功能和神经递质水平的影响[J].疑难病杂志,2021,20(2):182-186.
|
|
|
|